COVID-19 RESILIENCE FINANCE CERTIFICATION SCHEME
Industrial Bank Co., Ltd. Hong Kong Branch
Industrial Bank COVID-19 Response Bond 2020 ("COVID-19 Bond")
兴业银行 2020 年疫情防控债券
HKQAA Reference Number: 14731493-CA,14731524-CA
HKQAA-F1258-HKO-1E-OB 29 May 2020 (#4082536) | Page 1 |
COVID-19 RESILIENCE FINANCE CERTIFICATION SCHEME
Industrial Bank Co., Ltd. (hereinafter referred to as Industrial Bank) was established in Fuzhou City, Fujian Province in 1988 with a registered capital of 20.774 billion yuan and listed on the Shanghai Stock Exchange in 2007 (stock code: 601166). It's one of the first joint-stock commercial banks approved by the State Council and the People's Bank of China, and it's also the first Equator Bank in China. Now it has grown into a mainstream commercial banking group with banking as its main business and multiple fields such as trust, financial lease, funds, futures, asset management, consumer finance, research and consulting, and digital finance covered, ranking among the top 30 banks in the world and Fortune Global 500.
Use of Proceeds
Overall | |||||||||||
Percentage of proceeds | 100% | ||||||||||
committed for COVID- | |||||||||||
19 resilience | |||||||||||
Eligible Project | ∙ Support the working capital of hospitals or medical service providers | ||||||||||
Category for COVID-19 | |||||||||||
resilience | ∙ Support the production of preventive medical clothing, medical masks and disinfectants | ||||||||||
∙ Support pharmaceutical companies and for the production, R&D and distribution of | |||||||||||
medicines or vaccination | |||||||||||
∙ Support the production of medical equipment / vehicles | |||||||||||
∙ Support a stable supply of essentials during the pandemics | |||||||||||
∙ Support renovation work of hospitals | |||||||||||
The use of the | % | Use of proceeds | |||||||||
remaining proceeds | |||||||||||
0% | N/A, as 100% of the proceeds will be committed for COVID-19 resilience | ||||||||||
Refinancing | ☑ Yes, refinancing involved | ||||||||||
An estimate of the share | Which investments or | Expected look-back | |||||||||
of proceeds for re- | project portfolios may be | period1 for refinanced | |||||||||
financing | refinanced | project | |||||||||
100% | Loans to Eligible Project | The value date of all | |||||||||
Categories for COVID-19 | eligible loans is after 1st | ||||||||||
resilience as defined in | February 2020 | ||||||||||
"Use of Proceeds" section | |||||||||||
of this COVID-19 | |||||||||||
Resilience Finance | |||||||||||
Certification Scheme | |||||||||||
Framework Statement | |||||||||||
Template (the "Template") | |||||||||||
No, refinancing not involved. | |||||||||||
Declaration | ☑ We committed that proceeds will not be allocated to activities stated in Project Exclusion | ||||||||||
List (reference with IFC Exclusion List) | |||||||||||
(Replicate the table below for more than one eligible project category) |
Name of Eligible Project Category: Support the working capital of hospitals or medical service providers
1 Look back period refers to a maximum period in the past that an Issuer will look back to identify assets/earlier disbursements to such eligible projects that will be included in the reporting
HKQAA-F1258-HKO-1E-OB 29 May 2020 (#4082536) | Page 2 |
COVID-19 RESILIENCE FINANCE CERTIFICATION SCHEME
Intended benefit to | Corresponding SDG | SDG 3 | ||||||
resilience of COVID-19 | ||||||||
Social issues | The COVID-19 outbreak threatens the well-being of the world's | |||||||
population, especially those with limited access to health and | ||||||||
medical services | ||||||||
Target Population | Given the widespread nature of the COVID-19 pandemic, the | |||||||
(i.e. the beneficiary) | asset is expected to benefit the general populace. Benefits | |||||||
would be especially expected for those most vulnerable to the | ||||||||
COVID-19, including those with limited access to health and | ||||||||
medical services | ||||||||
Intended Social | The eligible loans are expected to create positive health | |||||||
Outcome | outcomes potentially as a result of improved access to health | |||||||
and medical service | ||||||||
Eligibility criteria | ∙ Loans to support the working capital of hospitals or medical service providers | |||||||
Key Performance | KPI (unit) | How to measure the | ||||||
Indicator (KPI) | KPI (Key underlying methodology and/or assumptions, e.g. | |||||||
baseline) | ||||||||
Number of companies | When IB identify the potential eligible loan portfolio, all of | |||||||
supported | the Eligible loans under the portfolio already align with the | |||||||
Overall objective: Increase | overall objective KPIs (e.g. maintenance original service | |||||||
access to essential health | level / expansion the production capacity). The overall | |||||||
care services | objective KPIs will be recorded in the Eligible Loan list. | |||||||
Relevant branches or departments will check if there are | ||||||||
any material changes on the Eligible Loan, and report to the | ||||||||
working group. The material changes will be recorded in the | ||||||||
Eligible Loan list. | ||||||||
KPI measurement - | International Standard | |||||||
Reference standard | National Standard | |||||||
Industry Standard | ||||||||
☑Self-development Standard | ||||||||
Others, Please specify: _____________________________________ | ||||||||
Any significant | Yes, please specify the risk and mitigation measure: | |||||||
environmental and | ||||||||
social risk constituted | ☑No significant environmental and social risk identified | |||||||
by this type of project | ||||||||
activities |
Name of Eligible Project Category: Support the production of preventive medical clothing, medical masks and disinfectants
Intended benefit to | Corresponding SDG | SDG 3 | ||||
resilience of COVID-19 | ||||||
Social issues | The COVID-19 outbreak threatens the well-being of the world's | |||||
population, especially those with limited access to medical and | ||||||
preventive equipment | ||||||
Target Population | Given the widespread nature of the COVID-19 pandemic, the | |||||
(i.e. the beneficiary) | asset is expected to benefit the general populace. Benefits | |||||
would be especially expected for those most vulnerable to the | ||||||
COVID-19, including those with limited access medical and | ||||||
preventive equipment | ||||||
Intended Social | The Eligible loans are expected to create positive health | |||||
Outcome | outcomes potentially as a result of reduction in the spread of the | |||||
virus among users of the medicine, equipment and supplies | ||||||
Eligibility criteria | ∙ Loans to support the production of preventive medical clothing, medical masks and | |||||
disinfectants | ||||||
Key Performance | KPI (unit) | How to measure the KPI (Key underlying methodology | ||||
Indicator (KPI) | and/or assumptions, e.g. baseline) | |||||
Number of companies | When IB identify the potential eligible loan portfolio, all of | |||||
HKQAA-F1258-HKO-1E-OB | 29 May 2020 (#4082536) | Page 3 |
COVID-19 RESILIENCE FINANCE CERTIFICATION SCHEME
supported | the Eligible loans under the portfolio already align with the | ||
Overall objective: Increase | overall objective KPIs (e.g. maintenance original service | ||
the production capacity of | level / expansion the production capacity). The overall | ||
preventive medical clothing, | objective KPIs will be recorded in the Eligible Loan list. | ||
medical masks and | Relevant branches or departments will check if there are | ||
disinfectants | any material changes on the Eligible Loan, and report to | ||
the working group. The material changes will be recorded | |||
in the Eligible Loan list. | |||
KPI measurement - | International Standard | ||
Reference standard | National Standard | ||
Industry Standard | |||
☑Self-development Standard | |||
Others, Please specify: _____________________________________ | |||
Any significant | Yes, please specify the risk and mitigation measure: | ||
environmental and | ☑No significant environmental and social risk identified | ||
social risk constituted | |||
by this type of project | |||
activities |
Name of Eligible Project Category: Support pharmaceutical companies and for the production, R&D and distribution of medicines or vaccination
Intended benefit to | Corresponding SDG | SDG 3 | ||||||
resilience of COVID-19 | ||||||||
Social issues | The COVID-19 outbreak threatens the well-being of the world's | |||||||
population, especially those with limited access to medicine or | ||||||||
vaccination | ||||||||
Target Population | Given the widespread nature of the COVID-19 pandemic, the | |||||||
(i.e. the beneficiary) | asset is expected to benefit the general populace. Benefits | |||||||
would be especially expected for those most vulnerable to the | ||||||||
COVID-19, including those with limited access to medicine or | ||||||||
vaccination | ||||||||
Intended Social | The Eligible loans are expected to create positive health | |||||||
Outcome | outcomes potentially as a result of the pharmaceutical, medical | |||||||
and vaccine research and development | ||||||||
Eligibility criteria | ∙ Loans to support pharmaceutical companies and for the production, R&D and | |||||||
distribution of medicines or vaccination | ||||||||
Key Performance | KPI (unit) | How to measure the KPI (Key underlying methodology | ||||||
Indicator (KPI) | and/or assumptions, e.g.? baseline) | |||||||
Number of companies | When IB identify the potential eligible loan portfolio, all of | |||||||
supported | the Eligible loans under the portfolio already align with the | |||||||
Overall objective: Contribute | overall objective KPIs (e.g. maintenance original service | |||||||
to medical and | level / expansion the production capacity). The overall | |||||||
pharmaceutical research | objective KPIs will be recorded in the Eligible Loan list. | |||||||
and development, including | Relevant branches or departments will check if there are | |||||||
but not limited to COVID-19 | any material changes on the Eligible Loan, and report to | |||||||
test, vaccines and/or other | the working group. The material changes will be recorded | |||||||
medications intended to | in the Eligible Loan list. | |||||||
alleviate symptoms of the | ||||||||
infectious virus | ||||||||
KPI measurement - | International Standard | |||||||
Reference standard | National Standard | |||||||
Industry Standard | ||||||||
☑Self-development Standard | ||||||||
Others, Please specify: _____________________________________ | ||||||||
Any significant | Yes, please specify the risk and mitigation measure: | |||||||
environmental and | ||||||||
social risk constituted | ☑No significant environmental and social risk identified | |||||||
by this type of project | ||||||||
activities | ||||||||
Name of Eligible Project Category: Support the production of medical equipment / vehicles | ||||||||
HKQAA-F1258-HKO-1E-OB | 29 May 2020 (#4082536) | Page 4 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
Industrial Bank Co. Ltd. published this content on 30 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 October 2020 01:29:03 UTC